报告期内，公司主营业务稳定发展，但受行业竞争加剧及医疗集采持续推进等影响，报告期内自产检测 试剂产品增值税税率调整为13%，上述因素叠加导致分子诊断试剂的收入有所下降。 硕世生物(688399.SH)披露2025年度业绩快报，公司实现营业总收入3.4亿元，同比下降2.64%;实现归属 于母公司所有者的净亏损3971.03万元;实现归属于母公司所有者的扣除非经常性损益的净亏损1.04亿 元。 ...

硕世生物(688399.SH)披露2025年度业绩快报，公司实现营业总收入3.4亿元，同比下降2.64%;实现归属 于母公司所有者的净亏损3971.03万元;实现归属于母公司所有者的扣除非经常性损益的净亏损1.04亿 元。 报告期内，公司主营业务稳定发展，但受行业竞争加剧及医疗集采持续推进等影响，报告期内自产检测 试剂产品增值税税率调整为13%，上述因素叠加导致分子诊断试剂的收入有所下降。 ...

报告期内，公司主营业务稳定发展，但受行业竞争加剧及医疗集采持续推进等影响，报告期内自产检测 试剂产品增值税税率调整为13%，上述因素叠加导致分子诊断试剂的收入有所下降。公司持续推进降本 增效措施，充分挖掘提质增效潜力，预计综合毛利率较上年同期基本保持稳定。 格隆汇2月27日丨硕世生物(688399.SH)公布2025年年度业绩快报，报告期内，公司实现营业总收入 34,038.04万元，同比下降2.64%；实现归属于母公司所有者的净利润-3,971.03万元，同比亏损扩大 3,770.86万元；实现归属于母公司所有者的扣除非经常性损益的净利润-10,383.16万元，同比亏损扩大 3,199.45万元。 ...

证券代码：688399 证券简称：硕世生物 公告编号：2026-004 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ?经财务部门初步测算，预计2025年度实现归属于母公司所有者的净利润为-2,940万元到-4,400万元，与 上年同期（法定披露数据）相比，将扩大亏损2,739.83万元到4,199.83万元。 ?预计2025年度归属于母公司所有者的扣除非经常性损益的净利润为-8,190万元到-12,280万元，与上年 同期（法定披露数据）相比，将扩大亏损1,006.29万元到5,096.29万元。 一、本期业绩预告情况 （3）本次业绩预告未经审计。 二、上年同期业绩情况 （一）2024年度公司实现利润总额为418.72万元。归属于母公司所有者的净利润为-200.17万元。归属于 母公司所有者的扣除非经常性损益的净利润为-7,183.71万元。 （二）2024年度基本每股收益为-0.02元(该数据为追溯调整后金额，公司于2025年6月实施2024年度权益 分派，以资本公积金向全体股东每10股转增4.8股， ...

报告期内，公司归属于母公司所有者的净利润和归属于母公司所有者的扣除非经常性损益的净利润较上 期亏损扩大，主要由于：（一）报告期内，公司主营业务稳定发展，但受行业竞争加剧及医疗集采持续 推进等影响，报告期内自产检测试剂产品增值税税率调整为13%，上述因素叠加导致分子诊断试剂的收 入有所下降。公司持续推进降本增效措施，充分挖掘提质增效潜力，预计综合毛利率较上年同期基本保 持稳定。（二）随着近年来公司加大应收账款的催收力度，长账龄应收账款账面余额逐年减少。报告期 内，公司应收款项减值准备转回较上年同期减少。 格隆汇1月30日丨硕世生物(688399.SH)公布，经财务部门初步测算，预计2025年度实现归属于母公司所 有者的净利润为-2,940万元到-4,400万元，与上年同期（法定披露数据）相比，将扩大亏损2,739.83万元 到4,199.83万元。预计2025年度归属于母公司所有者的扣除非经常性损益的净利润为-8,190万元 到-12,280万元，与上年同期（法定披露数据）相比，将扩大亏损1,006.29万元到5,096.29万元。 ...

报告期内，公司归属于母公司所有者的净利润和归属于母公司所有者的扣除非经常性损益的净利润较上 期亏损扩大，主要由于：（一）报告期内，公司主营业务稳定发展，但受行业竞争加剧及医疗集采持续 推进等影响，报告期内自产检测试剂产品增值税税率调整为13%，上述因素叠加导致分子诊断试剂的收 入有所下降。公司持续推进降本增效措施，充分挖掘提质增效潜力，预计综合毛利率较上年同期基本保 持稳定。（二）随着近年来公司加大应收账款的催收力度，长账龄应收账款账面余额逐年减少。报告期 内，公司应收款项减值准备转回较上年同期减少。 格隆汇1月30日丨硕世生物(688399.SH)公布，经财务部门初步测算，预计2025年度实现归属于母公司所 有者的净利润为-2,940万元到-4,400万元，与上年同期（法定披露数据）相比，将扩大亏损2,739.83万元 到4,199.83万元。预计2025年度归属于母公司所有者的扣除非经常性损益的净利润为-8,190万元 到-12,280万元，与上年同期（法定披露数据）相比，将扩大亏损1,006.29万元到5,096.29万元。 ...

Core Viewpoint - Ruiang Gene is facing a significant crisis due to the legal troubles of its controlling shareholders, which has led to a drastic decline in revenue and a loss of investor trust [1][2][3]. Governance Crisis - The turmoil began with a healthcare fraud investigation related to the lung cancer drug "Taris" in July 2021, where a subsidiary was implicated in altering genetic test results for insurance fraud [1][2]. - Despite the legal issues, the governance structure remains largely unchanged, with family control persisting, raising concerns about the effectiveness of internal controls [2][8]. Performance Collapse - The company anticipates a revenue drop of 27.36% to 29.84% in 2025, with a projected net loss nearing 60 million yuan [1]. - In the first half of 2025, revenue fell by 22.29%, and net profit decreased by 61.46%, with significant declines in both molecular diagnostic reagent sales and testing services [3][9]. - The financial strain has led to increased accounts receivable impairment and asset write-downs, further eroding profitability [3][9]. Future Challenges - The outcome of the legal proceedings against the controlling shareholders could impact the stability of control within the company [4][11]. - Rebuilding trust will be a lengthy process, and the company faces fundamental challenges such as customer attrition and financial strain [4][11]. - The case of Ruiang Gene serves as a warning for the entire precision medicine industry, emphasizing the importance of integrity and trust in maintaining public confidence [5][11].

Core Viewpoint - Ruiang Gene forecasts an annual revenue of 170 million to 176 million yuan for 2025, indicating a significant decline in profit due to various factors [1] Group 1: Revenue and Profit Decline - The company expects a revenue decrease of approximately 66.31 million to 72.31 million yuan in 2025, representing a year-on-year decline of 27.36% to 29.84% [1] - The decline in revenue has led to a reduction in gross profit [1] Group 2: Factors Contributing to Decline - Increased competition in the in vitro diagnostics industry and specific events affecting the company have negatively impacted revenue [1] - Slower payment collection from downstream clients due to the medical industry environment has resulted in increased provisions for credit impairment losses on accounts receivable [1] - The suspension of the molecular diagnostic reagent R&D center and industrialization project, with no plans for resumption, has led to impairment losses being recognized [1] - Performance declines in subsidiaries Shanghai Yuanqi Bio and Wuhan Baitai have prompted the company to recognize goodwill impairment losses and asset impairment losses, respectively, due to changes in the external market environment [1] Group 3: Tax Asset Adjustments - The significant decline in performance for both the parent and subsidiary companies has led to a reassessment of future taxable income, resulting in the write-off of previously recognized deferred tax assets [1]

南财智讯1月23日电，睿昂基因发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润 为-3990.69万元至-5986.03万元；预计2025年全年归属于上市公司股东的扣除非经常性损益的净利润 为-4990.69万元至-6986.03万元。报告期内，公司实现归属于母公司所有者的净利润和归属于母公司所 有者的扣除非经常性损益的净利润同比出现较大幅度的下滑，主要有以下四个方面的原因：1、受体外 诊断行业竞争加剧以及本公司特殊事件的影响，2025年营业收入较上年下降约6,630.62万元至7,230.62万 元，同比减少27.36%至29.84%，营业收入下降导致毛利金额下降；2、报告期内，受医疗行业环境影 响，下游客户回款变慢，公司根据坏账政策增加计提应收账款信用减值损失；3、报告期内，（1）公司 分子诊断试剂研发中心及产业化建设项目暂停，且暂无续建计划，公司判断其存在减值迹象，对其计提 减值损失；（2）由于外部市场环境发生变化，子公司上海源奇生物本期业绩进一步下滑，公司结合未 来经营情况的判断，对该子公司的商誉计提减值损失；（3）由于外部市场环境发生变化，子公司武汉 百泰本期业绩进一步下滑，公司判断其 ...

Core Viewpoint - The company, Zhijiang Biology, confirmed that it does not currently engage in brain-computer interface (BCI) related business activities [1] Group 1: Company Overview - Zhijiang Biology's main business focuses on molecular diagnostic reagents and equipment [1] - The applications of the company's products include medical clinical diagnosis, public health safety, entry-exit inspection and quarantine, and food safety [1] - The company has not expanded into the brain-computer interface sector [1]